← Eichor
Study identifier: NCT06779773 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Condition: Geographic Atrophy · Macular Degeneration  ·  Sponsor: Astellas Pharma Global Development, Inc.

PhaseN/A
Planned participants500
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people …

This description comes directly from the study's public registry record.

Talk to the study team

Astellas Pharma Global Development, Inc.  ·  800-555-5555  ·  Astellas.registration@astellas.com

Always discuss trial participation with your own doctor first.

Locations (65)

Phoenix Retina Clinical Trials, LLCPhoenix, Arizona, United StatesWithdrawn
Retinal Consultants of AZPhoenix, Arizona, United StatesRecruiting
Retina Macula Institute of ArizonaScottsdale, Arizona, United StatesRecruiting
The Retina PartnersEncino, California, United StatesWithdrawn
Harvard Eye AssociatesLaguna Hills, California, United StatesRecruiting
University of California Irvine Medical CenterOrange, California, United StatesRecruiting
Retina Consultants of Southern CARedlands, California, United StatesRecruiting
Retinal Consultants Medical Group IncSacramento, California, United StatesRecruiting
Retina Macula InstituteTorrance, California, United StatesRecruiting
Rocky Mountain Lions Eye InstituteAurora, Colorado, United StatesRecruiting
Retina Consultants of Southern ColoradoColorado Springs, Colorado, United StatesRecruiting
Colorado Retina Associates, PLLCLakewood, Colorado, United StatesRecruiting

+ 53 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06779773